Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer

Overview

The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment. The main criterion is a prioritization of 4 items per patient from a list of 8 expectations regarding the objectives of their treatment: treatment efficacy, life expectancy, autonomy, daily activities, social activities, heaviness of treatment, toxicity, economics.

Full Title of Study: “Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer : PRIORITY Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2019

Detailed Description

For the primary endpoint assessment, this self-administered patient questionnaire will used an opinion scale (Not at all, A little, Moderately, Enough, Many) to explore the eight domains. Next to the completion of the expectations questionnaire, patients will have to order 4 of the different 8 items that they prioritized in regard of the first line treatment that has just been prescribed by their physician.

Secondary endpoint will focus on those 8 proposed expectations of patients at different periods of time since treatment initiation. Patients' priorities will be compared to physician's priorities (using the same prioritization grid) before medical treatment and after 3 months of treatment and to younger patients' priorities (18-69 years). Associations between elderly patients' characteristics (social, medical…) and their priorities will be search.

Interventions

  • Other: Consultation, evaluation questionnaire
    • Consultation, evaluation questionnaire
  • Other: Geriatric consultation, evaluation questionnaire
    • Geriatric consultation, evaluation questionnaire

Arms, Groups and Cohorts

  • Elderly patient (70 years and older)
  • Young patient (18 years – 69 years)

Clinical Trial Outcome Measures

Primary Measures

  • Priorities of patients aged 70 and over and receiving first medical treatment for cancer.
    • Time Frame: Day 0 initiation of treatment
    • Main criteria is a prioritization of 4 items selected from a list of 8 expectations regarding the objectives of their treatment : efficacy , life expectancy , autonomy, daily activities , social activities, cumbersome treatment , toxicity, economics
  • Priorities of patients aged 70 and over and receiving first medical treatment for cancer
    • Time Frame: 3 months after initiation of treatment
    • Main criteria is a prioritization of 4 items selected from a list of 8 expectations regarding the objectives of their treatment : efficacy , life expectancy , autonomy, daily activities , social activities, cumbersome treatment , toxicity, economics .

Secondary Measures

  • Intra- individual reproducibility of the prioritization grid regarding the initial measurement of priorities of the elderly.
    • Time Frame: Day 0 initiation of treatment
  • Describe expectations of patients at initiation of treatment
    • Time Frame: Day 0 initiation of treatment
  • Describe expectations of patients 3 months after initiation of treatment
    • Time Frame: 3 months after initiation of treatment
  • Describe priorities and expectations of patients, at 6 months after initiation of treatment
    • Time Frame: 6 months after initiation of treatment
  • Describe priorities and expectations of patients, at 12 months after initiation of treatment
    • Time Frame: 12 months after initiation of treatment
  • Describe 3 months after initiation of treatment, the rate of stable patients in their priorities
    • Time Frame: 3 months after initiation of treatment
  • Describe 6 months after initiation of treatment, the rate of stable patients in their priorities
    • Time Frame: 6 months after initiation of treatment
  • Describe 12 months after initiation of treatment, the rate of stable patients in their priorities
    • Time Frame: 12 months after initiation of treatment
  • Overall survival, according to priorities changing or not
    • Time Frame: 3 months after initiation of treatment
  • Compare priorities of older subjects compared to younger patients or physician’s priorities
    • Time Frame: 3 months after initiation of treatment

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female:

1. Age ≥ 70 years

2. Aged 18-69 years (case population)

2. ECOG / performance status 0-3 (WHO).

3. First line of medical oncology treatment (chemotherapy, targeted therapy, hormone therapy, combination):

1. Neo-adjuvant setting,

2. Adjuvant setting: previous neo-adjuvant treatment is allowed,

3. Metastatic setting: previous neo-adjuvant and/or adjuvant treatment are allowed,

4. Solid tumors (breast, colorectal, kidney, lung, prostate, sarcoma, and ovarian) and lymphoma (indolent and aggressive).

5. Life expectancy of more than 3 months.

6. Patients potentially compliant with the rules of the follow-up study.

7. Patients affiliated to a social security scheme.

8. Patients who received clear information from the investigator on the study and had not refused to participate.

Exclusion Criteria

1. Exclusive surgery treatment.

2. Exclusive radiotherapy treatment or in combination with oncological medical treatment (concomitant radio-chemotherapy or radio-hormonotherapy).

3. Previous first line of oncological medical treatment in the same indication as the one concerned by the inclusion:

1. Neo-adjuvant setting: previous line(s) of neo-adjuvant medical treatment,

2. Adjuvant setting: previous line(s) of adjuvant medical treatment,

3. Metastatic setting: previous line(s) of metastatic medical treatment,

4. Supportive care without specific medical treatment

5. Previous or ongoing cancer under treatment at the time of inclusion.

6. Patient already included in this study

7. Patient who for psychological, psychiatric, social, family or geographical reasons could not be regularly monitored according to the criteria of the study; patient private of liberty or under guardianship.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut Bergonié
  • Collaborator
    • Fondation Université de Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • SOUBEYRAN Pierre-Louis, MD, PhD, p.soubeyran@bordeaux.unicancer.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.